Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765321000039/mck-20210331.htm
May 2022
April 2022
April 2022
February 2022
February 2022
February 2022
January 2022
November 2021
October 2021
September 2021
Fourth-Quarter | Year-to-Date | |||||||||||||||||||||||||||||||||||||
($ in millions, except per share amounts) | FY21 | FY20 | Change | FY21 | FY20 | Change | ||||||||||||||||||||||||||||||||
Revenues | $ | 59,142 | $ | 58,535 | 1 | % | $ | 238,228 | $ | 231,051 | 3 | % | ||||||||||||||||||||||||||
Income (loss) from Continuing Operations1 | 666 | 1,015 | (34) | (4,538) | 906 | (601) | ||||||||||||||||||||||||||||||||
Adjusted Earnings1,2 | 810 | 745 | 9 | 2,788 | 2,716 | 3 | ||||||||||||||||||||||||||||||||
Earnings (loss) per Diluted Share1 | 4.15 | 5.82 | (29) | (28.26) | 4.99 | (666) | ||||||||||||||||||||||||||||||||
Adjusted Earnings per Diluted Share1,2 | 5.05 | 4.27 | 18 | 17.21 | 14.95 | 15 | ||||||||||||||||||||||||||||||||
1Reflects continuing operations attributable to McKesson, net of tax 2Represents a non-GAAP financial measure; refer to the reconciliations of non-GAAP financial measures included in accompanying schedules |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765321000039/mck-20210331.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Mckesson Corp.
Mckesson Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Rating
Learn More![]()
CRITICAL ACCOUNTING POLICIES AND ESTIMATES We consider an accounting estimate to be critical if the estimate requires us to make assumptions about matters that were uncertain at the time the accounting estimate was made and if different estimates that we reasonably could have used in the current period, or changes in the accounting estimate that are reasonably likely to occur from period to period, could have a material impact on our financial condition or results from operations.
Any material changes in key assumptions, including failure to meet business plans, negative changes in government reimbursement rates, deterioration in the U.S. and global financial markets, an increase in interest rates or an increase in the cost of equity financing by market participants within the industry or other unanticipated events and circumstances, may decrease the projected cash flows or increase the discount rates and could potentially result in an impairment charge.
Operating profit and operating profit margin were unfavorably impacted by customer mix and a decrease in net cash proceeds received of $180 million representing our share of antitrust legal settlements.
SDG&A includes opioid-related costs of $114 million, primarily related to litigation expenses, and increased expenses due to our business acquisitions and to support growth, partially offset by a gain from an escrow settlement of $97 million representing certain indemnity and other claims related to our 2017 acquisition of Rexall Health and a credit of $90 million for the derecognition of a liability related to the tax receivable agreement ("TRA") payable to the shareholders of Change Healthcare, Inc. ("Change"); Goodwill impairment charges of $1.8 billion in our European Retail Pharmacy ("European RP") and European Pharmaceutical Distribution ("European PD") reporting units within the International segment.
Material changes to key assumptions and estimates can decrease the projected cash flows or increase the discount rates and have resulted in impairment charges of certain long-lived assets as disclosed in Financial Note 4, "Restructuring, Impairment, and Related Charges," to the accompanying consolidated financial statements included in this Annual Report on Form 10-K, and could potentially result in future impairment charges.
As of the testing date,...Read more
U.S. Pharmaceutical 2021 vs. 2020...Read more
Operating profit and operating profit...Read more
Other risks, expenses and future...Read more
We benefited from demand for...Read more
Operating activities for the year...Read more
Corporate expenses, net for 2021...Read more
Indicators that are considered include...Read more
Generally, a decline in estimated...Read more
Our ongoing consideration of all...Read more
Gross profit was favorably impacted...Read more
Corporate 2021 vs. 2020 Corporate...Read more
Additionally, operating profit was favorable...Read more
2020 vs. 2019 Operating loss...Read more
See Item 1 - Business...Read more
Medical-Surgical Solutions 2021 vs. 2020...Read more
2020 vs. 2019 Operating profit...Read more
2020 vs. 2019 Corporate expenses,...Read more
Revenues for this segment were...Read more
Operating activities for the year...Read more
The declines in estimated future...Read more
We also saw increased demand...Read more
On July 29, 2020, we...Read more
Subsequently, during the first quarter,...Read more
Costs related to contracts without...Read more
Gross profit and gross profit...Read more
Gross Profit Gross profit increased...Read more
McKESSON CORPORATION FINANCIAL REVIEW (Continued)...Read more
During the first quarter of...Read more
Gross profit was unfavorably impacted...Read more
The initiative consisted of multiple...Read more
Gross profit increased for the...Read more
Additionally, we made a cash...Read more
In future periods, unfavorable foreign...Read more
The remaining charges primarily were...Read more
As such, we accounted for...Read more
The various responses we put...Read more
NEW ACCOUNTING PRONOUNCEMENTS New accounting...Read more
Net loss for the year...Read more
Consolidated working capital improved at...Read more
McKESSON CORPORATION FINANCIAL REVIEW (Continued)...Read more
Interest Expense Interest expense decreased...Read more
Because of the many uncertainties...Read more
Because of the many uncertainties...Read more
That Form 8-K should be...Read more
A material default in payment,...Read more
On April 25, 2018, we...Read more
The contractual obligations table above...Read more
These factors could make our...Read more
While we are not able...Read more
Refer to the "Goodwill Impairment"...Read more
2020 vs. 2019 Operating profit...Read more
On July 1, 2019, upon...Read more
Operating activities for the year...Read more
This change was not material...Read more
McKESSON CORPORATION FINANCIAL REVIEW (Continued)...Read more
In connection with this transaction,...Read more
Income Tax (Benefit) Expense We...Read more
Any significant changes in assumptions...Read more
RxTS is a new reportable...Read more
McKESSON CORPORATION FINANCIAL REVIEW (Continued)...Read more
The State of New York...Read more
Consolidated working capital decreased at...Read more
Specialty drug volumes increased, but...Read more
Under the Domination Agreement, the...Read more
Additionally, as required under the...Read more
The vaccine and related ancillary...Read more
However, there can be no...Read more
In discussing our operating results,...Read more
We have also set up...Read more
This was partially offset by...Read more
The redemption value is the...Read more
At March 31, 2019, both...Read more
Following the Split-off, we do...Read more
The receipt of any payments...Read more
McKESSON CORPORATION FINANCIAL REVIEW (Continued)...Read more
However, the likelihood of a...Read more
We have seen continued improvement...Read more
In future periods, fair value...Read more
While the ultimate amount of...Read more
2020 vs. 2019 Operating profit...Read more
These assumptions require significant judgment...Read more
2020 vs. 2019 Medical-Surgical Solutions...Read more
Revenues for this segment were...Read more
We expanded employee medical benefits...Read more
2020 vs. 2019 RxTS revenues...Read more
We believe that our future...Read more
2020 vs. 2019 U.S. Pharmaceutical...Read more
If our current estimate of...Read more
Our reported income tax expense...Read more
This collaboration expedited the shipment...Read more
These facilities can scale to...Read more
Share Repurchase Plans The Board...Read more
International 2021 vs. 2020 International...Read more
We believe that we have...Read more
Refer to Item 1A -...Read more
During the year ended March...Read more
Our reported income tax (benefit)...Read more
In estimating future taxable income,...Read more
Goodwill and Long-Lived Assets: As...Read more
Determination of recoverability of intangible...Read more
Assumptions and estimates about future...Read more
Additionally, we have a robust...Read more
This was partially offset by...Read more
In connection with the Split-off,...Read more
McKESSON CORPORATION FINANCIAL REVIEW (Continued)...Read more
Restructuring Initiatives and Long-Lived Asset...Read more
Total operating expenses for the...Read more
Currently, all of our intangible...Read more
Refer to Financial Note 13,...Read more
An increase or decrease of...Read more
Other income, net also increased...Read more
During the first quarter of...Read more
If we had used the...Read more
Subsequently, pharmaceutical distribution volumes decreased...Read more
2020 vs. 2019 International revenues...Read more
Medical-Surgical Solutions 2021 vs. 2020...Read more
We generally recognize employee severance...Read more
(3)$8 million was accrued within...Read more
RELATED PARTY BALANCES AND TRANSACTIONS...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Mckesson Corp provided additional information to their SEC Filing as exhibits
Ticker: MCK
CIK: 927653
Form Type: 10-K Annual Report
Accession Number: 0000927653-21-000039
Submitted to the SEC: Wed May 12 2021 4:09:57 PM EST
Accepted by the SEC: Wed May 12 2021
Period: Wednesday, March 31, 2021
Industry: Wholesale Drugs Proprietaries And Druggists Sundries